Abstract -We describe the case of a 69-year old male with an EGFR-positive Imatinib refractory sacral chordoma with synchronous lung metastases, treated with erlotinib, a first-generation EGFR inhibitor. After disease progression following firstline Imatinib and a combination therapy with everolimus plus metformin, we made a challenge with an EGFR tyrosine kinase inhibitor (EGFR TKI), erlotinib. Despite a brief clinical benefit, the patient presented a rapid clinical deterioration leading to death, after 8 weeks of treatment.
A 69-year old man was referred to our institution for a refractory sacral chordoma. First diagnosis was performed in April 2012 through an incisional biopsy of the primitive tumor; at presentation, synchronous lung metastases were radiologically detected. The primitive mass was surgically resected en-bloc with distal sacrum (distal sacrectomy): pathology report confirmed the presence of a 12, 5 cm chordoma, infiltrating the surrounding soft tissues and the overlying skin with ulceration. IHC (immunohistochemistry) revealed a Brachyury, PDGFR-β and EGFR 2+ positive tumor (R pharmDx™ Dako kit) with evidence of pS6 phosphorylation in more than 70% of cells.
He received a first-line systemic therapy with a tyrosine kinase inhibitor (TKI), Imatinib 400mg, in another institution; everolimus was added to imatinib for a slight progression of disease (PD) after 4 months, reaching a disease stability (SD) for 16 months; the TKI was eventually substituted with metformin with SD. The patient was then referred to our institution: he presented a rapid clinical deterioration of the clinical status with dyspnea on exertion; a low flow oxygentherapy on demand was so provided. We performed a 18 FDG-PET evaluation on July 2015 that revealed lung, bone and pelvic diffuse pathological accumulations. Afterwards, in the absence of therapeutic alternative options for a good performing patient, a challenge with an EGFR inhibitor, Erlotinib 150mg daily, was proposed. A better tolerance to exercise with a reduction of dyspnea on exertion and no more continuous, daily demand of oxygen support was reported. However, despite a transient clinical benefit, the patient presented a new rapid clinical deterioration after 8 weeks of treatment, leading to death in September 2015. DISCUSSION Chordoma is a rare mesenchymal tumor arising from the remnants of notochord, an embryonic midline structure common to all Chordata-Phylum members. In higher vertebrates including humans, the notochord gets ossified and contributes to the formation of vertebrae, persisting as nucleus pulposus of intervertebral discs (1); however, microscopic foci can remain in the cranial and caudal portion of the spine. Chordoma is a rare bone cancer, accounting 1-4% of all bone malignancies; it arises mainly from the axial skeleton, affecting most commonly cranial and caudal bone midline sites like sacrum and skull base (2) . The clinical behavior of this tumor is insidious for the unpredictable possibility of spread on bone and neural structures; moreover, the indolent and clinically silent course delays the diagnosis until advanced disease. Mostly, spine chordomas involve S4-S5 or coccygeal region protruding anteriorly into the pelvis with late onset neurological symptoms, due to neural roots compression (3) . Chordoma rarely presents as metastatic at first (Tommaso.depas@ieo.it) Università degli Studi di Salerno diagnosis: OS seems to be poorly affected by metastatic progression and local control appears to be correlated more to the prognosis (4). The backbone of therapy for the localized disease is surgery with wide margins without violation of tumor capsule, with a significant impact on DFS and OS (5). Concerning medical treatment, chordoma seems to be insensitive to cytotoxic chemotherapy; in a series of 33 cases published by Azzarelli (6) , no chemotherapeutic regimen induced a significant tumor respons though a potential response to continuous infusion ifosfamide was demonstrated in high-grade de-differentiated tumors (7) as well as with combination regimen containing anthracyclines, platinum-compounds and alkylating drugs (8) . This intrinsic chemo-resistance paves the way to different anti-tumor approaches, designed from biologic features and molecular characterization of chordoma. Kilgore S. showed a high expression of cyclin D1, a key regulator of cell cycle-progression in a series of 26 chordoma samples (9); overexpression of CDK4, p53 and MDM2 was detected in 20-56% of sacral and skull-base chordoma, with a poor prognostic significance (10) . Membrane growth factor receptors (TKRs) were demonstrated to be highly expressed in chordomas: scatter factor/ hepatocyte growth factor receptor (c-Met), epidermal growth factor receptor (EGFR/HER1) and different phosphorylated platelet-derived growth factor receptors (PDGFRs) seem to play a key role in tumor proliferation (11) ; this suggests a potential role of tyrosine-kinase receptor inhibitor as therapeutics. Hence, a high-level copy number gain of 7p12 band (EGFR locus) and EGFR expression (67-81%) have been demonstrated; TKRs (PDGFR-a, c-Met, EGFR) are variously expressed in 97% of the recurrence samples analyzed (12) . Furthermore, this molecular stigmata are potentially druggable. TKIs targeting angiogenesis have shown to be active against chordoma; this may probably reflect a cross-inhibition of different overlapping molecular patterns (13) . On this subject, Casali et. al detected an anti-tumor effect in term of tumor liquefaction, metabolic and clinical response of imatinib mesylate 800mg daily; he supposed an activity mediated by PDGFRβ-inhibition (14) . Similarly, a response to sunitinib 37,5 mg daily was demonstrated in a multicenter phase-II trial: 44% of chordoma patients achieved a SD concurrent to a qualitative decrease in tumor density; this pattern of response is considered to be characteristic of tumor response to VEGF-directed therapy (15) . Additionally, EGFR-inhibitors have shown a clinical activity, particularly in the second-line setting after imatinib failure (16) . Results from a phase II trial reported a modest antitumor activity of lapatinib administered at 1500mg continuously until progression or unacceptable toxicity in advanced EGFR-positive chordomas; the clinical benefit rate was 22,2% by RECIST for the intention-to-treat population (17) . Siu evaluated the activity of erlotinib on a patient-derived chordoma xenograft; he showed a strong druggable activation of EGFR: exposure of tumor cells to erlotinib resulted in a dimensional anti-tumor response concurrent to a reduction of phosphorylation of Tyr845 residue, thus supporting a favorable clinical usage (18) . Based on this molecular notion, a compassionate use of Erlotinib for relapsed-refractory chordoma can be proposed. Few recent case reports showed a clinical activity of erlotinib (Tab1) but its benefit has not been evaluated in a prospective trial. Indeed, a sustained response to erlotinib of a clivus-arising chordoma after imatinib failure has been described by Houessinon A. (19) : a 28 months continuous partial-response was reported, the longest described in literature in this setting.
EGFR INHIBITION IN A PRETREATED SACRAL CHORDOMA: A ROLE FOR ERLOTINIB? CASE REPORT AND A BRIEF REVIEW OF LITERATURE

CONCLUSION
Our case report shows no clear clinical response to erlotinib in an imatinib-refractory sacral chordoma. Few clinical data are available to support the choice of Erlotinib in this setting, with discordant experiences reported. Therefore, a prospective trial comparing erlotinib Vs. standard therapy in different setting is warranted, considering the high rate of EGFR-positive chordomas and preclinical encouraging data. Furthermore, EGFR mutational status prognostic significance and predictive role should be clarified.
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